Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2016 Oct 8

PMID 27713351

Citations 5

Authors

Marino Venerito

Thomas Wex

Peter Malfertheiner

Affiliations

Soon will be listed here.

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely prescribed medications in the World. A frequent complication of NSAID use is gastroduodenal bleeding. Risk factors for gastroduodenal bleeding while on NSAID therapy are age, prior peptic ulcer and co-medication with anti-platelet agents, anticoagulants, glucocorticosteroids and selective serotonin-reuptake inhibitors (SSRI). Prevention strategies for at-risk patients include the use of the lowest effective dose of NSAIDs, co-therapy with proton-pump inhibitors and/or the use of a COX-2 selective agent. Treatment of Helicobacter pylori infection is beneficial for primary prophylaxis of NSAID-induced gastroduodenal bleeding in NSAID-naive patients. For patients with cardiovascular risk factors requiring NSAIDs, naproxen should be selected. In very high risk patients for both gastrointestinal and cardiovascular complications NSAID therapy should be avoided altogether.

Citing Articles

The Protective Effect of Walnut Oligopeptides against Indomethacin-Induced Gastric Ulcer in Rats.

Liu R, Zhu N, Hao Y, Liu X, Kang J, Mao R Nutrients. 2023; 15(7).

PMID: 37049515 PMC: 10096596. DOI: 10.3390/nu15071675.

Interaction of Oxicam Derivatives with the Artificial Models of Biological Membranes-Calorimetric and Fluorescence Spectroscopic Study.

Maniewska J, Czyznikowska Z, Szczesniak-Siega B, Michalak K Membranes (Basel). 2022; 12(8).

PMID: 36005706 PMC: 9412344. DOI: 10.3390/membranes12080791.

Increased susceptibility of aging gastric mucosa to injury and delayed healing: Clinical implications.

Tarnawski A, Ahluwalia A World J Gastroenterol. 2018; 24(42):4721-4727.

PMID: 30479459 PMC: 6235800. DOI: 10.3748/wjg.v24.i42.4721.

Utilization of gastroprotective strategies for nonsteroidal anti-inflammatory drug-induced gastrointestinal events in a major teaching hospital.

Lee H, Chua S, Mahadeva S Ther Clin Risk Manag. 2016; 12:1649-1657.

PMID: 27877048 PMC: 5110204. DOI: 10.2147/TCRM.S119722.

Therapeutic potential of hydrazones as anti-inflammatory agents.

Kajal A, Bala S, Sharma N, Kamboj S, Saini V Int J Med Chem. 2014; 2014:761030.

PMID: 25383223 PMC: 4207405. DOI: 10.1155/2014/761030.

References

Hunt R, Harper S, Callegari P, Yu C, Quan H, Evans J . Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther. 2003; 17(2):201-10. DOI: 10.1046/j.1365-2036.2003.01407.x. View

Halter F, Tarnawski A, Schmassmann A, Peskar B . Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut. 2001; 49(3):443-53. PMC: 1728453. DOI: 10.1136/gut.49.3.443. View

Rassen J, Choudhry N, Avorn J, Schneeweiss S . Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009; 120(23):2322-9. PMC: 2818789. DOI: 10.1161/CIRCULATIONAHA.109.873497. View

Anderson J, Adams C, Antman E, Bridges C, Califf R, Casey Jr D . ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to.... Circulation. 2007; 116(7):e148-304. DOI: 10.1161/CIRCULATIONAHA.107.181940. View

Huang J, Sridhar S, Hunt R . Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002; 359(9300):14-22. DOI: 10.1016/S0140-6736(02)07273-2. View

Bresalier R, Sandler R, Quan H, Bolognese J, Oxenius B, Horgan K . Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352(11):1092-102. DOI: 10.1056/NEJMoa050493. View

Chan F, Abraham N, Scheiman J, Laine L . Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet.... Am J Gastroenterol. 2008; 103(11):2908-18. DOI: 10.1111/j.1572-0241.2008.02200.x. View

Sorensen H, Mellemkjaer L, Blot W, Nielsen G, Steffensen F, McLaughlin J . Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000; 95(9):2218-24. DOI: 10.1111/j.1572-0241.2000.02248.x. View

Gabriel S, Jaakkimainen L, Bombardier C . Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991; 115(10):787-96. DOI: 10.7326/0003-4819-115-10-787. View

10.

Laine L, Hennekens C . Proton pump inhibitor and clopidogrel interaction: fact or fiction?. Am J Gastroenterol. 2009; 105(1):34-41. DOI: 10.1038/ajg.2009.638. View

11.

Hallas J, Dall M, Andries A, Andersen B, Aalykke C, Hansen J . Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006; 333(7571):726. PMC: 1592384. DOI: 10.1136/bmj.38947.697558.AE. View

12.

Dalton S, Johansen C, Mellemkjaer L, Norgard B, Sorensen H, Olsen J . Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003; 163(1):59-64. DOI: 10.1001/archinte.163.1.59. View

13.

Barkun A, Bardou M, Kuipers E, Sung J, Hunt R, Martel M . International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010; 152(2):101-13. DOI: 10.7326/0003-4819-152-2-201001190-00009. View

14.

Chan A, Manson J, Albert C, Chae C, Rexrode K, Curhan G . Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006; 113(12):1578-87. DOI: 10.1161/CIRCULATIONAHA.105.595793. View

15.

Rude M, Chey W . Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between?. Gastroenterology. 2009; 137(3):1168-71. DOI: 10.1053/j.gastro.2009.07.011. View

16.

Vergara M, Catalan M, Gisbert J, Calvet X . Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005; 21(12):1411-8. DOI: 10.1111/j.1365-2036.2005.02444.x. View

17.

Kearney P, Baigent C, Godwin J, Halls H, Emberson J, Patrono C . Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553):1302-8. PMC: 1473048. DOI: 10.1136/bmj.332.7553.1302. View

18.

Ho P, Maddox T, Wang L, Fihn S, Jesse R, Peterson E . Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301(9):937-44. DOI: 10.1001/jama.2009.261. View

19.

Juurlink D, Gomes T, Ko D, Szmitko P, Austin P, Tu J . A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180(7):713-8. PMC: 2659819. DOI: 10.1503/cmaj.082001. View

20.

Singh G, Triadafilopoulos G . Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999; 56:18-24. View